Neurofilament Light Chain (NfL) Mechanism in Neurodegeneration

Neurofilament Light Chain (NfL) in Neurodegeneration

Overview

[Neurofilament Light](/biomarkers/neurofilament-light-chain-nfl) Chain (NfL) is a critical cytoskeletal protein primarily expressed in large myelinated axons, where it plays an essential role in maintaining axonal structural integrity and caliber. In neurodegenerative diseases, NfL has emerged as one of the most promising axonal damage biomarkers, detectable in cerebrospinal fluid (CSF) and blood. Elevated NfL levels reflect the degree of axonal injury across a spectrum of neurodegenerative conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and multiple sclerosis (MS). [@mattsson2019]

NfL Biology and Structure

Molecular Characteristics

Neurofilaments are intermediate filaments that constitute a major component of the neuronal cytoskeleton. The neurofilament triplet consists of three subunits: [@preische2019]

• Neurofilament Light Chain (NfL) - ~61 kDa, the most abundant and soluble subunit
• Neurofilament Medium Chain (NfM) - ~95 kDa
• Neurofilament Heavy Chain (NfH) - ~200 kDa, heavily phosphorylated

NfL serves as the foundational scaffold onto which NfM and NfH assemble to form the mature neurofilament heteropolymer. The protein is encoded by the NEFL gene located on chromosome 8p21.2 and is expressed predominantly in large-diameter axons of motor and sensory [neurons](/entities/neurons). [@benatar2018]

Physiological Function

...

Neurofilament Light Chain (NfL) in Neurodegeneration

Overview

[Neurofilament Light](/biomarkers/neurofilament-light-chain-nfl) Chain (NfL) is a critical cytoskeletal protein primarily expressed in large myelinated axons, where it plays an essential role in maintaining axonal structural integrity and caliber. In neurodegenerative diseases, NfL has emerged as one of the most promising axonal damage biomarkers, detectable in cerebrospinal fluid (CSF) and blood. Elevated NfL levels reflect the degree of axonal injury across a spectrum of neurodegenerative conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and multiple sclerosis (MS). [@mattsson2019]

NfL Biology and Structure

Molecular Characteristics

Neurofilaments are intermediate filaments that constitute a major component of the neuronal cytoskeleton. The neurofilament triplet consists of three subunits: [@preische2019]

• Neurofilament Light Chain (NfL) - ~61 kDa, the most abundant and soluble subunit
• Neurofilament Medium Chain (NfM) - ~95 kDa
• Neurofilament Heavy Chain (NfH) - ~200 kDa, heavily phosphorylated

NfL serves as the foundational scaffold onto which NfM and NfH assemble to form the mature neurofilament heteropolymer. The protein is encoded by the NEFL gene located on chromosome 8p21.2 and is expressed predominantly in large-diameter axons of motor and sensory [neurons](/entities/neurons). [@benatar2018]

Physiological Function

In healthy neurons, neurofilaments provide structural support for axonal transport and help maintain the diameter of large myelinated axons, which directly correlates with conduction velocity. NfL is phosphorylated at specific serine and threonine residues, which modulates its assembly dynamics and interaction with other cytoskeletal proteins. [@pilotto2019]

Mechanism of NfL Release in Neurodegeneration

NfL is released into extracellular spaces and subsequently into CSF and blood through a well-characterized sequence of events: [@khalil2018]

Key Release Mechanisms

Axonal degeneration - Primary mechanism in Wallerian degeneration and traumatic injury

Neuronal death - Release from dying neurons in neurodegenerative diseases

Exosome-mediated release - Active secretion via extracellular vesicles

Impaired axonal transport - Build-up leading to overflow release

[Blood-brain barrier](/entities/blood-brain-barrier) (BBB) disruption - Enables NfL to enter peripheral circulation

NfL in Specific Neurodegenerative Diseases

Alzheimer's Disease (AD)

In Alzheimer's disease, NfL levels correlate with: [@giovannelli2022]

• Disease progression - Rising NfL predicts cognitive decline
• Brain atrophy - Strong correlation with hippocampal and cortical volume loss
• Amyloid and [tau](/proteins/tau) pathology - NfL elevation follows amyloid deposition but precedes clinical symptoms

Multiple studies have demonstrated that CSF NfL increases 10-15 years before clinical diagnosis in individuals with autosomal dominant AD mutations. [@mollenhauer2021]

Key references: Mattsson et al. (2019)[@mattsson2019], Preische et al. (2019)[@preische2019]

Parkinson's Disease (PD)

In Parkinson's disease, NfL serves as: [@bacioglu2016]

• A marker of nigrostriatal degeneration
• A predictor of cognitive decline and dementia development
• A potential differentiator from atypical parkinsonisms

Elevated NfL in PD correlates with: [@zetterberg2020]

• Hoehn and Yahr stage
• Motor symptom severity
• Dopaminergic neuron loss on DAT imaging

Key References:

• [Pilotto et al., Serum NfL in PD (2019)](https://doi.org/10.1212/WNL.0000000000007868)
• [Mollenhauer et al., NfL and PD progression (2021)](https://doi.org/10.1016/j.parkreldis.2021.03.014)

Amyotrophic Lateral Sclerosis (ALS)

NfL is particularly elevated in ALS, where it:

• Serves as a disease progression marker
• Correlates with survival time
• Reflects upper and lower motor neuron involvement

CSF NfL in ALS can be 5-10x higher than in healthy controls, making it one of the most robust biomarkers for this condition.

Key References:

• [Benatar et al., Serum NfL in ALS (2018)](https://doi.org/10.1016/S1474-4422(18)30114-2)
• [Giovannelli et al., CSF NfL as ALS biomarker (2022)](https://doi.org/10.1002/ana.26376)

Frontotemporal Dementia (FTD)

In FTD, NfL:

• Distinguishes FTD from AD in ambiguous cases
• Correlates with disease severity
• Associates with specific subtypes (higher in behavioral variant FTD)

Multiple Sclerosis (MS)

In MS, NfL serves as:

• A marker of acute axonal injury
• A predictor of future disability progression
• A tool for monitoring treatment response

Clinical Utility of NfL

Diagnostic Value

| Disease | Diagnostic Utility | Sensitivity | Specificity |
|---------|---------------------|-------------|-------------|
| ALS | High | 85-90% | 80-85% |
| MS (active disease) | High | 70-80% | 75-85% |
| AD (prodromal) | Moderate | 60-70% | 70-80% |
| PD (with dementia) | Moderate | 65-75% | 70-80% |
| FTD | Moderate | 60-70% | 75-85% |

Prognostic Applications

Disease progression prediction - Rising NfL trajectories predict faster progression

Survival estimation - High NfL correlates with shorter survival in ALS and FTD

Treatment response monitoring - NfL reduction with successful treatment

Monitoring Applications

• Clinical trials - NfL as secondary endpoint for neuroprotective drug efficacy
• Individual patient management - Tracking treatment response over time
• Biomarker-guided clinical decisions - NfL thresholds informing therapeutic choices

Therapeutic Implications

NfL as Therapeutic Target

While NfL itself is not a direct therapeutic target, understanding its dynamics has led to:

Neuroprotective strategies - Targeting upstream causes of axonal injury

Biomarker-guided trials - Using NfL as inclusion criterion or endpoint

NfL-Guided Clinical Trials

Several clinical trials now incorporate NfL as:

• Enrollment criteria - Selecting patients with evidence of active axonal injury
• Primary or secondary endpoint - Measuring neuroprotective drug effects
• Pharmacodynamic marker - Demonstrating target engagement

Key References:

• [Cummings et al., NfL in AD clinical trials (2020)](https://doi.org/10.1016/j.jadr.2020.100011)

Emerging Therapeutic Approaches

• Axonal protection - Agents targeting excitotoxicity, oxidative stress, and mitochondrial dysfunction
• Myelin repair - Remyelination strategies to protect axons
• Neuroinflammation modulation - Reducing secondary axonal damage

Methodological Considerations

Assay Platforms

• Simoa (Single Molecule Array) - Most sensitive, detects pg/mL levels
• ELISA - Traditional method, higher detection limits
• Electrochemiluminescence - Meso Scale Discovery platform

Sample Types

CSF - More direct reflection of CNS pathology, higher concentrations

Blood - Less invasive, requires ultra-sensitive assays

Plasma vs. serum - Comparable levels, slight differences in baseline

Confounding Factors

• Age - NfL increases with normal aging (~1% per year)
• Renal function - Impaired clearance elevates blood NfL
• Physical activity - Acute exercise can transiently increase NfL
• Traumatic brain injury - Can cause acute NfL elevation

Future Directions

Research Priorities

Standardization - Establishing reference standards across assay platforms

Longitudinal studies - Characterizing NfL trajectories across disease stages

Combination biomarkers - NfL + other markers (tau, neurogranin, YKL-40)

Genetic modifiers - Understanding how NEFL polymorphisms affect NfL levels

Clinical Implementation

• Point-of-care testing - Developing rapid NfL assays for clinical use
• Integration into clinical guidelines - Incorporating NfL into diagnostic criteria
• Personalized medicine - NfL-guided treatment decisions

Cross-Linking

NfL intersects with numerous other neurodegenerative mechanisms:

• [Amyloid-beta](/mechanisms/amyloid-cascade) - Downstream axonal injury marker in AD
• [Tau pathology](/mechanisms/tau-pathology) - Co-elevated in tauopathies
• [Alpha-synuclein](/proteins/alpha-synuclein) - Synergistic markers in synucleinopathies
• [TDP-43](/proteins/tdp-43-protein) - Co-pathology in ALS/FTD
• [Neuroinflammation](/mechanisms/neuroinflammation) - NfL as neuroinflammation-sensitive marker
• [Microglia](/cell-types/microglia) - Activation-mediated axonal damage

Conclusion

Neurofilament Light Chain represents one of the most validated and clinically useful biomarkers in neurodegenerative disease. Its release reflects the fundamental pathological process of axonal injury that underlies virtually all neurodegenerative conditions. As assay technologies continue to improve and clinical experience accumulates, NfL is poised to become a routine part of the neurodegenerative disease diagnostic and monitoring armamentarium.

See Also

• [Amyloid-beta](/mechanisms/amyloid-cascade)
• [Tau pathology](/mechanisms/tau-pathology)
• [Alpha-synuclein](/proteins/alpha-synuclein)
• [TDP-43](/proteins/tdp-43-protein)
• [Neuroinflammation](/mechanisms/neuroinflammation)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research (2024-2026)

• [Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders.](https://pubmed.ncbi.nlm.nih.gov/41828591/) (2026 Mar 4) - Int J Mol Sci
• [Obstructive sleep apnea, biomarker profiles, and clinical progression in Parkinson's disease: Longitudinal effects of CPAP therapy.](https://pubmed.ncbi.nlm.nih.gov/41499940/) (2026 Mar) - Sleep Med
• [miR-137-5p-Loaded Milk-Derived Small Extracellular Vesicles Modulate Oxidative Stress, Mitochondrial Dysfunction, and Neuroinflammatory Responses in an In Vitro Alzheimer's Disease Model.](https://pubmed.ncbi.nlm.nih.gov/41754992/) (2026 Feb 18) - Pharmaceutics
• [Associations of plasma biomarkers with longitudinal co-pathologies in Alzheimer's disease and cerebral small vessel disease comorbidity.](https://pubmed.ncbi.nlm.nih.gov/41478816/) (2026 Feb) - J Prev Alzheimers Dis
• [Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism.](https://pubmed.ncbi.nlm.nih.gov/41620763/) (2026 Jan 31) - J Neuroinflammation

References

[Mattsson et al., CSF NfL in preclinical AD (2019)](https://doi.org/10.1001/jamaneurol.2019.1359)

[Preische et al., Serum NfL predicts neurodegeneration in preclinical AD (2019)](https://doi.org/10.1038/s41591-019-0358-x)

[Benatar et al., Neurofilament light chain in ALS (2018)](https://doi.org/10.1016/S1474-4422(18)30114-2)

[Pilotto et al., Serum NfL in Parkinson's disease (2019)](https://doi.org/10.1212/WNL.0000000000007868)

[Khalil et al., Neurofilament light chain: a biomarker for neurodegeneration (2018)](https://doi.org/10.1038/s41582-018-0058-z)

[Giovannelli et al., CSF NfL in ALS (2022)](https://doi.org/10.1002/ana.26376)

[Mollenhauer et al., NfL in PD progression (2021)](https://doi.org/10.1016/j.parkreldis.2021.03.014)

[Cummings et al., NfL in AD clinical trials (2020)](https://doi.org/10.1016/j.jadr.2020.100011)

[Bacioglu et al., NfL in blood and CSF as marker in AD (2016)](https://doi.org/10.1016/j.cell.2016.08.057)

[Zetterberg & Blennow, NfL in CSF and blood (2020)](https://doi.org/10.1002/acn3.51228)

Pathway Diagram

The following diagram shows the key molecular relationships involving Neurofilament Light Chain (NfL) Mechanism in Neurodegeneration discovered through SciDEX knowledge graph analysis: